Drug profile · INN
obeticholic acid
OCALIVA
obeticholic acid (OCALIVA) is a bile acid receptor fxr agonist. Associated with Amdipharm Mercury (Australia) Pty Limited. Route of administration: oral. Current US regulatory status: approved.
Drug details — obeticholic acid
- US status
- approved
- Class
- Alimentary tract and metabolism (A05)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
obeticholic acid (OCALIVA) is a bile acid receptor fxr agonist. Associated with Amdipharm Mercury (Australia) Pty Limited. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bile acid receptor FXR agonist
Primary target: Bile acid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | unknown | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is obeticholic acid?
obeticholic acid (OCALIVA) is a bile acid receptor fxr agonist. Associated with Amdipharm Mercury (Australia) Pty Limited. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for obeticholic acid?
OCALIVA is a marketed brand name for obeticholic acid. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of obeticholic acid?
obeticholic acid has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.